Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers H > Headlines for Hana Biosciences, Inc. > News item |
Hana reiterated at buy by Jefferies
Hana Biosciences Inc. was reiterated at s buy with a $13 price target by Jefferies & Co., Inc. analyst Adam Walsh. The company acquired worldwide rights to Menadione, a preclinical candidate for treatment and prevention of epidermal growth factor receptor inhibitors-associated skin rash. According to the analyst, the compound does not pose any Zensana patent infringement problems. The 45-day window for GlaxoSmithKline to bring suit closes Oct. 23. Shares of the South San Francisco, Calif.-based development-stage biopharmaceutical company were down 20 cents, or 2.44%, at $8.01. (Nasdaq: HNAB)
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.